The use of oral pilocarpine in xerostomiaand sjögren's syndrome

https://doi.org/10.1016/S0049-0172(99)80002-XGet rights and content

Objectives

To analyze the role of oral pilocarpine in the treatment of xerostomia of Sjögren's syndrome (SS).

Methods

The medical literature was reviewed for all studies using oralpilocarpine to treat xerostomia caused by SS or radiotherapy registered in the MedLine Silver Platter database from 1966 to 1998.

Results

All the studies identified excluded elderly individuals with cardiac or pulmonary disease. Patients with postradiation xerostomia and incomplete resection of the salivary glands were more likely to benefit from oral pilocarpine when there was sufficient residual glandular function than patients with radical surgery for head and neck cancer (HNC). However, patients with SS and other inflammatory disorders seemed to benefit from oral pilocarpine, when compared with patients with postradiation xerostomia. The optimal dose of oral pilocarpine, which was less likely to cause side effects, was 5 mg four times daily. A recent multi-center study in SS patients suggests that oral pilocarpine is effective and safe for long-term administration. Although some studies did not show evidence for increased salivary gland secretion rate as measured by sialometry, symptoms improved, perhaps because of increased secretion from the minor salivary glands or better conditioning of the oral mucosa.

Conclusion

Oral pilocarpine is likely to benefit patients with SS by reducingthe symptoms of xerostomia, even if the salivary gland secretion rate does not increase. Further controlled studies are needed in patients with SS and should include elderly patients with cardiovascular disease treated with moderate doses of oral pilocarpine.

References (24)

  • FoxP.C. et al.

    Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction

    Oral Surg Oral Med Oral Pathol

    (1986)
  • GreenspanD. et al.

    Effectiveness of pilocarpine in postradiation xerostomia

    Cancer

    (1987)
  • Cited by (44)

    • Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations

      2007, Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology
      Citation Excerpt :

      The drug stimulates water and electrolyte flow, and perhaps also other salivary components such as mucin. Secretory stimulation by these agents requires that residual functional salivary gland tissue be present; for review see Nusair and Rubinow.151 The side effects include excessive sweating, rhinitis, and urinary and gastrointestinal (GI) disturbances.

    • Salivary gland gene therapy

      2006, Dental Clinics of North America
      Citation Excerpt :

      Pilocarpine and civemilene are muscarinic receptor agonists that are used to stimulate salivary secretions in patients with remaining parenchymal tissue. These treatments help to improve symptoms locally [68], but these are not useful for managing the immune features of SS. Develop new treatment strategies for SS is important.

    • Sjögren syndrome in obstetric and gynecology: Literature review

      2006, Journal de Gynecologie Obstetrique et Biologie de la Reproduction
    • Minor gland saliva flow rate and proteins in subjects with hyposalivation due to Sjögren's syndrome and radiation therapy

      2005, Archives of Oral Biology
      Citation Excerpt :

      The reduced function of the salivary glands in pSS is due to lymphatic infiltration of the organs.3 Patients with pSS are therefore expected to have some residual salivary function,4 and respond to stimulation of their major and minor salivary glands.5 In RT patients, the reduced secretion rates are due to irreversible, degenerative processes in the glands.

    View all citing articles on Scopus
    View full text